Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.12 USD | +2.65% | -5.50% | -10.05% |
Financials (USD)
Sales 2024 * | 461M | Sales 2025 * | 549M | Capitalization | 1.78B |
---|---|---|---|---|---|
Net income 2024 * | 135M | Net income 2025 * | 181M | EV / Sales 2024 * | 2.88 x |
Net cash position 2024 * | 459M | Net cash position 2025 * | 682M | EV / Sales 2025 * | 2.01 x |
P/E ratio 2024 * |
13.4
x | P/E ratio 2025 * |
10.1
x | Employees | 167 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.79% |
Latest transcript on Catalyst Pharmaceuticals, Inc.
1 day | +2.65% | ||
1 week | -5.50% | ||
Current month | -5.14% | ||
1 month | -3.88% | ||
3 months | +3.56% | ||
6 months | +18.50% | ||
Current year | -10.05% |
Managers | Title | Age | Since |
---|---|---|---|
Patrick McEnany
FOU | Founder | 77 | 01-12-31 |
Richard Daly
CEO | Chief Executive Officer | 62 | 15-02-18 |
Michael Kalb
DFI | Director of Finance/CFO | 53 | Dec. 31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick McEnany
FOU | Founder | 77 | 01-12-31 |
Donald Denkhaus
BRD | Director/Board Member | 78 | 15-02-18 |
David Tierney
BRD | Director/Board Member | 60 | 02-09-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.05% | 29 M€ | -3.64% | ||
0.32% | 27 M€ | -4.43% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 15.12 | +2.65% | 942,143 |
24-04-23 | 14.73 | -2.45% | 992,474 |
24-04-22 | 15.1 | -0.20% | 1,015,778 |
24-04-19 | 15.13 | -1.37% | 7,422,178 |
24-04-18 | 15.34 | -4.13% | 1,493,313 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.05% | 1.78B | |
-2.86% | 87.31B | |
+3.95% | 40.86B | |
-21.94% | 29.36B | |
+53.61% | 24.49B | |
-5.41% | 17.31B | |
-44.23% | 11.26B | |
-17.60% | 11.62B | |
-13.96% | 11.31B | |
+1.35% | 8.31B |
- Stock Market
- Equities
- CPRX Stock